Get Started

CAPR

NASD Capricor Therapeutics, Inc.
Nov 13, 2026 · 2:37 PM ET DELAYED Market Open

$9.55 ↓ -0.70 (-6.79%) Trading Down from the previous close of $10.24, $0.68 below the day’s high of $10.22

YTD change
-66.93%
vs 20-day SMA
+26.28%
vs 200-day SMA
-52.50%

Price ranges

Previous day
$9.87 $10.95
open $10.95 close $10.24
-$0.71 (-6.48%)
Today
$9.26 $10.22
open $10.21 now $9.55
-$0.67 (-6.51%)
Past week
$8.30 $11.23
from $8.60 now $9.55
+$0.95 (+10.99%)
Past month
$5.67 $11.23
from $7.27 now $9.55
+$2.28 (+31.29%)
This year
$2.96 $36.82
from $28.86 now $9.55
-$19.32 (-66.93%)

Price & Performance

-20.09 (-66.24%) / 6M

$1.73$11.99$22.26$32.52May 13Aug 14Nov 12

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good
  • The stock is 77.5% away from all-time highs of $42.50
  • CAPR is down 67% since the beginning of the year
  • CAPR is up 65% over the past 12 months
  • CAPR is up 31% over the past 1 month
  • 39% of all CAPR investors are betting against CAPR

CAPR reads not so good: price sits above one of the two key moving averages, the 12-month move is +77.5%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.73
Earnings momentum -99.1% Quarterly EPS growth
Quarterly change -99.1%

Valuation

P/E ratio N/A
Enterprise value $489.9M
Beta 0.64

Balance sheet & scale

IncomeN/A
RevenueN/A
Cash$197.6M
Debt$92.2K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $554.9M

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $467.06 -0.22%
MRNA Moderna, Inc. $231.35 -6.97%
RVMD Revolution Medicines, Inc. $176.35 -2.41%
ROIV Roivant Sciences Ltd. $39.99 -4.44%
BNTX BioNTech SE Sponsored ADR $85.04 -2.98%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.